Please select the option that best describes you:
What is your preferred first-line therapy for a patient with standard risk multiple myeloma?
Has the recent data presented at ASH affected your choice of regimen?
Would your choice differ between transplant-eligible and transplant-ineligible patients?
Answer from: Medical Oncologist at Community Practice
Tough question.
Let's do the easy ones first. The low risk (R-ISS 1) fit patient could be treated any number of ways with Bortezomib+Lenalidomide+Dexamethasone (RVd), Carfilzomib+Lenalidomide+Dexamethasone (KRd), or Daratumumab+Lenalidomide+Dexamethasone (Dara-Rd). Bortezomib can...
Sign in or Register to read more